TY - JOUR T1 - Application of Cancer Cell Reprogramming Technology to Human Cancer Research JF - Anticancer Research JO - Anticancer Res SP - 3367 LP - 3377 VL - 37 IS - 7 AU - XIU-YANG PAN AU - MING-HO TSAI AU - KENLY WUPUTRA AU - CHIA-CHEN KU AU - WEN-HSIN LIN AU - YING-CHU LIN AU - SHOTARO KISHIKAWA AU - MICHIYA NOGUCHI AU - SHIGEO SAITO AU - CHANG-SHEN LIN AU - KAZUNARI K. YOKOYAMA Y1 - 2017/07/01 UR - http://ar.iiarjournals.org/content/37/7/3367.abstract N2 - The cancer stem cell (CSC) hypothesis is an evolving concept of oncogenesis that has recently gained wide acceptance. By definition, CSCs exhibit continuous proliferation and self-renewal, and they have been proposed to play significant roles in oncogenesis, tumor growth, metastasis, chemoresistance, and cancer recurrence. The reprogramming of cancer cells using induced pluripotent stem cell (iPSC) technology is a potential strategy for the identification of CSC-related oncogenes and tumor-suppressor genes. This technology has some advantages for studying the interactions between CSC-related genes and the cancer microenvironment. This approach may also provide a useful platform for studying the mechanisms of CSCs underlying cancer initiation and progression. The present review summarizes the recent advances in cancer cell reprogramming using iPSC technology and discusses its potential clinical use and related drug screening. ER -